UBS Group AG Buys 11,198 Shares of Soleno Therapeutics, Inc. $SLNO

UBS Group AG lifted its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 7.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 169,506 shares of the company’s stock after buying an additional 11,198 shares during the quarter. UBS Group AG’s holdings in Soleno Therapeutics were worth $7,848,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Soleno Therapeutics by 1.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after buying an additional 189 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Soleno Therapeutics in the second quarter valued at about $25,000. Avanza Fonder AB increased its position in Soleno Therapeutics by 11.2% during the fourth quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock worth $148,000 after acquiring an additional 323 shares during the period. Principal Financial Group Inc. increased its position in Soleno Therapeutics by 11.9% during the third quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock worth $216,000 after acquiring an additional 340 shares during the period. Finally, New York State Common Retirement Fund raised its stake in Soleno Therapeutics by 2.4% in the 3rd quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock worth $1,055,000 after purchasing an additional 360 shares in the last quarter. 97.42% of the stock is currently owned by institutional investors.

Soleno Therapeutics Trading Up 0.0%

SLNO opened at $53.01 on Tuesday. The stock has a market capitalization of $2.76 billion, a price-to-earnings ratio of 29.95 and a beta of -2.22. The company has a quick ratio of 5.32, a current ratio of 5.62 and a debt-to-equity ratio of 0.10. Soleno Therapeutics, Inc. has a twelve month low of $29.43 and a twelve month high of $90.32. The company has a 50-day simple moving average of $45.26 and a 200 day simple moving average of $45.70.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.64 by $0.16. Soleno Therapeutics had a net margin of 33.70% and a return on equity of 22.85%. The firm had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. Analysts predict that Soleno Therapeutics, Inc. will post 3.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SLNO has been the subject of a number of recent research reports. Piper Sandler downgraded shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Wells Fargo & Company set a $53.00 price target on shares of Soleno Therapeutics and gave the company an “equal weight” rating in a research report on Friday, April 17th. Robert W. Baird downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Finally, Wall Street Zen lowered Soleno Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. Three analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $76.67.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.